Biotech Startups

1928 Diagnostics provides a cloud-based bioinformatics platform that transforms complex genomic sequencing data into actionable insights for researchers, healthcare providers, and organizations. The platform automates genomic analysis workflows, making advanced analytics accessible without requiring specialized computational expertise or on-site infrastructure.

1 investor

20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.

1 investor

20n develops computational systems that use machine learning and AI to predict DNA designs, turning biological data into usable information for industrial biotech and health applications. Its customers are industrial biotech firms producing fuels, materials, therapeutics, and flavors and fragrances through biological processes.

1 investor

23Strands works in precision medicine and genomics, and has launched Geneve Health Pty Ltd, a wholly owned entity focused on precision medicine for women's and reproductive health. The company aims to provide healthcare tailored to individual patients.

1 investor

2508 Biosciences develops therapeutics for the treatment of traumatic brain injury.

1 investor

2bull MeDiTherapy develops in-vitro diagnostic medical devices, including TAP, a blood test designed to detect thoracic and abdominal aortic aneurysms. The company focuses on early detection and monitoring diagnostics for cardiovascular disease.

1 investor

2cureX develops IndiTreat®, a 3D functional precision medicine test that grows patient-derived cancer cells as 3D microtumors (tumoroids) from a tumor biopsy to profile drug sensitivity and guide individualized therapy selection. The company serves oncologists and healthcare professionals, providing drug-response reports to inform cancer treatment decisions, and brings its diagnostic products through EU regulatory and reimbursement pathways.

1 investor

A biotech company focused on microbiome and metabolomics research for gastrointestinal health applications, with leadership and scientific advisory rooted in academic medicine and regulatory expertise.

1 investor

3billion provides genetic diagnostic services for rare diseases, using automated reanalysis and clinical review to increase diagnostic yield for healthcare providers and institutions. It works with providers across more than 70 countries.

1 investor

3Brain develops microchip-based technology for recording and analyzing cell activity in life science research, combining microelectronics with biology to enable precise real-time monitoring of electrogenic cells. The company serves researchers in academia and industry, operating in the bioelectronics and life sciences sector.

1 investor

3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.

1 investor

3D OrthoBiologic Solutions develops and commercializes 3D-printed bone graft scaffolds for surgery and 3D cell culture technologies, targeting the treatment of bone defects and diseases. Its work focuses on orthopedic and oral/maxillofacial reconstructive and regenerative medicine.

1 investor

3F is a Canadian circular economy company that diverts waste and converts it into products and ingredients, including offerings for the pet food industry. It focuses on sustainability and job creation in Newfoundland and Labrador.

1 investor

3Helix develops and sells collagen hybridizing peptides (CHP) and related conjugates for research and diagnostic applications. The company's products are designed to detect and bind denatured collagen chains in both laboratory and in vivo settings.

1 investor

3PBIOVIAN is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end biopharmaceutical manufacturing services for biotech and pharma companies. The company offers microbial and mammalian protein expression, viral vector production, cell therapy, plasmid DNA production, and fill & finish services across multiple locations in Spain, Finland, and the United States.

1 investor

3X4 Genetics provides direct-to-consumer genetic testing and personalized health recommendations based on DNA analysis, focusing on nutrient needs, disease prevention, weight management, and stress response. The company delivers actionable insights through a mobile app and optional practitioner consultations in the digital health and wellness sectors.

1 investor

402 provides a no-code platform for running common bioinformatics analyses such as RNA sequencing, protein folding, docking simulations, and variant detection, removing the need for coding or manual samplesheet formatting. It targets researchers and scientists who need to perform genomics and computational biology tasks without writing code.

1 investor

Laza Medical develops AI-powered robotic systems and imaging solutions for structural heart and electrophysiology procedures. The company serves interventional cardiologists and healthcare systems seeking to optimize clinical workflows.

1 investor

48Hour Discovery is a drug discovery company using chemically modified phage display technology to identify peptide leads with high affinity and specificity. It serves pharmaceutical companies and startups, taking peptide discovery projects from inception through synthesis, validation, and optimization for a range of protein and cell-based targets.

1 investor

4B Tech develops therapeutics for central nervous system and neurodegenerative diseases, focusing on neuroprotection, synaptic repair, and suppression of neuroinflammation to slow disease progression. Its approach targets the underlying pathophysiology of neural degeneration rather than specific disease causes.

1 investor

4bases develops clinically-validated diagnostic genetic tests, including companion diagnostics and tests for inherited gene mutations, used by healthcare professionals to support therapeutic decisions in precision and preventive medicine. The company operates as an ISO13485-certified, CE-IVD compliant in vitro diagnostics provider.

1 investor

4BIO Capital is an investment firm focused on early-stage advanced therapies targeting chronic disease. The team combines academic researchers, physician-scientists, and investment professionals with direct experience in gene therapy and clinical research.

1 investor

4C Medical develops minimally invasive medical devices for structural heart disease, including mitral and tricuspid valve treatments. The company serves interventional cardiologists and patients requiring catheter-based cardiac interventions.

1 investor

4C Biomed develops an immunological screening platform to identify drug targets for cancer immunotherapy development. The company serves pharmaceutical and biotech organizations working on novel cancer treatments.

1 investor